Secondary objectives

Secondary objectives evaluated (i) immunogenicity of a single MenACWY-TT dose in terms of percentage of participants with rSBA-MenA, rSBA-MenC, rSBA-MenW, and rSBA-MenY antibody titres ≥1:8, ≥1:128 and geometric mean titres (GMTs) at 1 month post-vaccination; (ii) the percentage of participants with anti-tetanus toxoid concentrations ≥0.1 international unit/mL, and geometric mean concentrations at 1 month post-vaccination; (iii) antibody persistence induced by MenACWY-TT in terms of the percentage of participants with rSBA-MenA, rSBA-MenC, rSBA-MenW, and rSBA-MenY titres ≥1:8, ≥1:128 and GMTs, 2 years after MenACWY-TT vaccination; (iv) safety and reactogenicity of one dose of MenACWY-TT.